Herpes zoster (HZ), a varicella-zoster virus reactivation, frequently complicates hematopoietic stem cell transplantation (HSCT). Its incidence, complications, and associated risk factors in 310 children undergoing HSCT were reviewed. In all, 61 of 201(32%) patients who had undergone allogeneic and 10 of 109 (9%) patients who had undergone autologous HSCT developed HZ. Of 90 VZV seropositive allogeneic patients, 50 (53%) developed HZ. Seven (17%) of 41 VZV seropositive autologous patients developed HZ. Although a substantial number of patients develop HZ in the early post-HSCT period, risk for HZ persists and HZ can occur up to 5 years post-HSCT. Risk factors for HZ included age 410 years (Po0.0001), allogeneic HSCT (Po0.001), and total body irradiation (TBI) (Po0.059) in allogeneic recipients. Of 37, 22 (59%) patients experienced an elevated alanine aminotransferase (ALT), unassociated with GVHD, in the month preceding HZ. Of the 48/64 patients (75%) hospitalized for treatment (median stay, 6 days; range, 2-39), length of stay was unaffected by donor type but increased by cutaneous dissemination and visceral involvement (P ¼ 0.023 and 0.034, respectively) in allogeneic patients. Consideration of HZ infection particularly in patients 410 years of age with elevated ALT after TBIconditioned allogeneic HSCT may permit earlier diagnosis and therapeutic intervention.
Introduction
Herpes zoster (HZ) infection is caused by the varicellazoster virus (VZV) and is a common complication following hematopoietic stem cell transplantation (HSCT). HZ infection represents a reactivation of latent VZV virus and usually presents as a localized dermatomal skin eruption, which may be treated with oral or intravenous antiviral therapies and often requires admission to hospital. There is significant morbidity from post-herpetic neuralgia, and prolonged pain and discomfort may be present for extended time periods following the disappearance of the skin lesions. 1 Infrequently, HZ infection is complicated by disseminated cutaneous involvement or visceral organ involvement with significantly increased morbidity and even mortality. 2, 3 The incidence of HZ in children following HSCT has been reported in the range of 23-67%, [4] [5] [6] [7] [8] [9] which is comparable to the incidence in adult HSCT recipients. Some studies have suggested that children develop post-HSCT HZ earlier than adults, 4, 5, 7 but other studies have demonstrated a later median time of onset. 9 HZ complications in the post-HSCT pediatric population have been reported with variable frequency.
Prior studies in adult HSCT recipients have identified several risk factors associated with HZ infection including underlying disease, 10 patient age, 11, 12 absence of antiviral prophylaxis, 13 conditioning with total body irradiation (TBI), 12 allogeneic HSCT, 11 and preceding acute or chronic graft-versus-host disease (aGVHD or cGVHD); 11, 13 however, the importance of these risk factors has been inconsistent in adult studies and even less well defined in children. The ability to identify a cohort of patients at particular risk for development of HZ and its complications would allow for more vigilant monitoring in that group and potentially earlier intervention with less subsequent morbidity and need for hospital admission. This process would be particularly aided by a reliable marker that could herald the onset of infection prior to the appearance of typical skin manifestations. In the literature, transaminitis prior to the development of skin rash has been described in cases where HZ involved visceral abdominal organs, and this portended a poor outcome. 2, 3 Leung et al., 9 describe a child with disseminated cutaneous HZ who had an elevated alanine aminotransferase (ALT) level noted at presentation and did not develop clinical hepatitis. Similarly, we noted that several of our patients had elevations in transaminase levels prior to onset of skin manifestations, but did not go on to develop visceral organ involvement. These observations suggested that otherwise unexplained transaminase elevation might serve as potential marker for pre-clinical HZ infection.
In the present retrospective study, we therefore examined a large cohort of post-HSCT pediatric patients in order to assess the incidence, complications, and treatment of HZ infection and to identify risk factors for HZ in this population. We also explored the hypothesis that elevation of serum aspartate aminotransferase (AST) and ALT levels antecede development of skin manifestations, and that such elevation should prompt consideration of HZ infection.
Methods

Patients and HSCT regimens
Data on all patients who underwent HSCT in the Pediatric HSCT Program at the Dana-Farber Cancer Institute/ Children's Hospital Boston between January 1995 and December 2002 were obtained from HSCT research Database and patient chart review after IRB approval. A total of 310 patients were included in the analysis. Patients undergoing allogeneic HSCT received either a matched sibling (6/6 HLA match), matched unrelated donor (6/6 HLA match), or mismatched (5/6 HLA match) bone marrow (BM) or peripheral blood stem cell (PBSC) transplant. Patients undergoing autologous HSCT received PBSC. Patients with acute leukemia, myelodysplastic syndromes, or chronic myelogenous leukemia who underwent allogeneic matched-sibling or unrelated donor transplantation were conditioned with total body irradiation (TBI) 1400 cGy and cyclophosphamide 120 mg/kg or 3.6 gm/m 2 , while the majority of patients with congenital diseases received busulfan 16/mg/kg and cyclophosphamide 200 mg/kg or 6 gm/m 2 (with or without equine antithymocyte globulin at 90 mg/kg). Patients undergoing matched sibling transplant all received cyclosporin at 1.5 mg/kg i.v. b.i.d. starting on day À2 with a target level of 150-200, and short course methotrexate (15 mg/m 2 on day 1 and 10 mg/m 2 on days 3, 6, and 11) for GVHD prophylaxis. Those with unrelated donors also received 1 mg/kg methylprednisolone IV from day þ 7 through day þ 21 tapered as tolerated thereafter. Patients with aplastic anemia and sibling donors were conditioned with cyclophosphamide 200 mg/kg or 6 g/m 2 and equine anti-thymocyte globulin at 90 mg/kg. Patients with a primary immune deficiency were conditioned with the busulfan regimen or did not receive conditioning. Patients who underwent an autologous HSCT received a variety of conditioning regimens including BEAM for Hodgkin's disease, 14 CD10/CD9-depleted autologous transplants for acute lymphoblastic leukemia, 15 and tandem HSCT for patients with high-risk neuroblastoma and other solid tumors. 16 Patients who had positive HSV titers received acyclovir (100 mg/m 2 from day À5 until day þ 24 or discharge) and those who had positive CMV titers or patients undergoing allogeneic HSCT whose donor had positive CMV titers received acyclovir (dose from day À2 until day þ 30 or discharge). A subset of patients (transplanted between January 1995 and December 1998) who were either CMV titer positive or patients undergoing allogeneic HSCT whose donor had positive CMV titers received gancyclovir (6 mg/kg, three times/week until day þ 120) in addition to acyclovir prophylaxis. Patients who underwent allogeneic HSCT had IgG levels checked no less frequently than every 3 weeks and received IVIG in a dose of 500 mg/kg for total IgG o400 mg/dl until two sequential unsupplemented levels 4400 mg/dl were recorded. A subset of patients who underwent unrelated donor allogeneic HSCTs (transplanted between January 1995 and December 1998) empirically received weekly IVIG at a dose of 500 mg/kg during hospitalization. After discharge, the above algorithm of checking levels and replacement was followed.
Definitions
Serologic status with respect to HZ was determined by enzyme-linked immunoabsorbent assay performed by the clinical laboratory using protocols in force at the time. During the time period addressed by this retrospective analysis, HZ serology was obtained for some patients as part of an initiative to determine susceptibility of the clinic population to infection in case of inadvertent exposure. Testing was neither routine nor required prior to HSCT; therefore, documentation of serologic status was not available for all HSCT patients. HZ infection was defined clinically by the appearance of typical cutaneous vesicular lesions in a dermatomal distribution7VZV isolation from these lesions or positive DFA stain irrespective of prior serologic status. Relapsed disease was defined as reappearance of classic lesions within 2 months of the first episode.
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Recurrent infection was defined as reappearance of classic lesions more than 2 months after the first episode. Cutaneous dissemination of HZ was defined as the subsequent appearance of lesions in noncontiguous dermatomes. 9 Visceral organ dissemination was defined as histological or culture evidence of organ involvement or clinical evidence of organ involvement in the absence of other identified pathogens that might have accounted for the clinical picture. 9 Post-herpetic neuralgia was defined as the need to provide ongoing pain medications to treat pain in a dermatomal distribution following the resolution of skin lesions. Transaminase elevation was defined as elevation above the upper limit of normal for age.
Patients were divided into two groups to evaluate the effect of immune status prior to HSCT. The first group was considered immunocompromised and consisted of all patients who had received chemotherapy for an underlying malignancy prior to undergoing HSCT or who had a primary immune deficiency. The second group, considered immunologically relatively intact, consisted of patients who underwent HSCT without prior therapy, including those who had myelodysplastic syndrome, chronic myelogenous leukemia in stable phase, aplastic anemia, hemoglobinopathies, and metabolic disorders. Acute and chronic GVHD were defined by standard criteria. 17, 18 Data analysis Conditional probabilities 19 for competing risk data were adopted for the incidence analysis of HZ infection, assuming that both recurrence and death without recurrence were competing events. Multiple HZ episodes in an individual patient were analysed as time to first infection, whereas preceding liver function test (transaminase levels) results and subsequent complications were considered for each episode. A subgroup analysis was also performed to estimate the incidence of HZ infection in patients with a documented positive VZV antibody titer prior to undergoing HSCT. Evaluation of the following potential risk factors (donor type (allogeneic vs autologous, matched sibling vs unrelated), age (410 vs p10), acute or chronic GVHD prior to HZ, immune status prior to HSCT (see Definitions section above), and conditioning with TBI) was performed using a proportional hazard regression model. The best subset procedure was used for the model selection. The association between disseminated cutaneous or visceral organ involvement and categorical transplant-related factors was evaluated using two-sided P-values from Fisher's exact test. In order to evaluate whether antiviral prophylaxis significantly affected the timing of HZ infection, a two-sample t-test on the log-transformed time length from HSCT to onset of HZ infection was performed. For each of four variables (aspartate aminotransferase (AST), alanine aminotransferase (ALT), white blood cell count (WBC), and platelet count (PLT)), three values were recorded. The earliest value available in the 4 weeks prior to diagnosis of HZ was recorded as the baseline value (time 1). A second value (time 2) was recorded midway between baseline and infection where possible, and the final value recorded was during active infection. Two mixed models for logtransformed values were fitted to evaluate the time effects on these values. One model used only values at time 1 and time 2 and the other used all three. In all cases, the actual date the value was obtained was used in the statistical analysis. To assess the relationship between donor type (allogeneic vs autologous, matched vs mismatched), age (410 vs p10), acute or chronic GVHD prior to HZ, immune status prior to HSCT, conditioning with TBI, and disseminated cutaneous or visceral organ involvement on length of hospital stay for treatment of HZ, a linear regression model was fitted on the log-transformed length of hospitalization.
Results
Patient demographics
All pediatric patients who received a HSCT between January 1995 and December 2002 at the Dana-Farber Cancer Institute/Children's Hospital Boston were reviewed. A total of 404 patients underwent HSCT. In all, 89 patients who had all of their follow-up performed at the referring institution were excluded. Five patients were excluded because they were transplanted from haploidentical family donors. Thus, 310 patients were included for analysis. A total of 201 patients underwent allogeneic HSCT, with 96 having sibling donors, 101 having unrelated donors, and four having phenotypically matched extended family donors. A total of 109 patients underwent an autologous HSCT.
Among those receiving allogeneic HSCT, patient age ranged from 0.17 to 21 years (median age 9 years) and underlying diagnoses included acute leukemia (n ¼ 98), chronic myelogenous leukemia (n ¼ 22), myelodysplastic syndrome (n ¼ 25), aplastic anemia (n ¼ 27), and other conditions (n ¼ 29) (See Table 1 for details). Of 131 patients receiving allogeneic HSCT for whom pre-HSCT serology could be documented, a positive VZV antibody titer was Table 1 Clinical characteristics of pediatric patients who underwent allogeneic HSCT in relation to post-HSCT HZ infection (9) 23 (17) 29 (14) a CNS tumor 1, Diamond-Blackfan anemia 2, Ewing sarcoma 2, NHL 2, Hodgkin's disease 3, Wiskott-Aldrich syndrome 2.
found in 96/131 (73%) patients. The characteristics of patients who developed HZ compared with those who did not are summarized in Table 1 .
In the autologous group, patient age ranged from 0.92 to 20 years (median age 5 years) and underlying diagnoses included acute leukemia (n ¼ 11), neuroblastoma (n ¼ 59), and other conditions (n ¼ 39) (see Table 2 for details). Of 63 patients receiving autologous HSCT for whom pre-HSCT serology could be documented, a positive VZV antibody titer was found in 41/63 (65%) patients. The characteristics of patients who developed HZ compared with those who did not are summarized in Table 2 . (Figure 1a) . Seven allogeneic patients experienced multiple HZ infections. Four of these cases were relapsed infections, while three were recurrent. One autologous patient experienced a recurrent HZ infection.
Incidence of HZ
We next decided to examine the incidence in the subset of patients felt to be at highest risk of VZV reactivation, namely those with documented previously positive VZV titers. A total of 90 allogeneic patients had documented seropositive titres. Of this group, 50 (53%) developed HZ. The incidence of infection in this cohort was 54% by 12 months (s. 
Frequency of complications
Medical record review did not always provide sufficient detail to determine what, if any, complications occurred in the 76 affected patients. Post-herpetic neuralgia occurred in 21 of 73 patients in whom sufficient information was available (29%; 95% CI ¼ 19%, 41%). Disseminated skin involvement occurred in 15 of 74 patients in whom sufficient information was available (20%; 95% CI ¼ 12%, 31%). Visceral organ involvement occurred in five of 75 patients in whom sufficient information was available (7%; 95% CI ¼ 2.2%, 15%). Target organs included liver, eye, and CNS, respectively, in three patients who had undergone unrelated donor SCT, lung in a patient who had undergone matched sibling SCT, and liver in a patient who had received an autologous SCT. HZ was the cause of death in the patient with lung involvement. Among the allogeneic SCT recipients, no new case of acute GVHD developed after the onset of HZ infection; whereas four patients developed chronic GVHD within 2 months following HZ infection.
Risk factors for VZV infection (Tables 3-5)
A total of 188 patients (HZ cohort, n ¼ 55, nonzoster cohort n ¼ 133) were treated with prophylactic acyclovir for positive HSV or CMV as per protocol. However, there was no statistical evidence that acyclovir prophylaxis affected the timing of onset of HZ in our models. Only one patient with HZ and 14 patients in the nonzoster cohort received gancyclovir prophylaxis from date of discharge until day þ 100. A previous history of chemotherapy or underlying primary immune deficiency leading to immune compromise (immune status group 1) was not a risk factor for the development or timing of onset of HZ. Patient age (410 vs p10) was a risk factor, with those patients age 410 years being at an increased risk for development of HZ (Po0.0001). Those patients undergoing allogeneic HSCT were more likely to develop HZ than those who underwent an autologous HSCT (P ¼ 0.001), although the type of donor (matched sibling vs unrelated donor) was not found to be significant in allogeneic cohort.
In considering the allogeneic cohort, the addition of ATG as part of the conditioning regimen was not a significant risk factor for the development of HZ. However, age 410 years remained significant and prior conditioning with TBI approached significance as risk factors for the development of HZ (P ¼ 0.0001 and 0.059, respectively).
In patients undergoing autologous HSCT, age 410 years continued to be a significant risk factor (P ¼ 0.015). Conditioning with TBI and tandem transplantation were found to be strongly associated (Po0.0001), such that these risk factors could not be analyzed independently; when examined together, they were not significant risk factors in the model.
We next determined whether presence of acute or chronic GVHD was associated with subsequent occurrence of HZ infection. Surprisingly, patients with acute or chronic GVHD prior to HZ infection experienced a smaller hazard of infection than those without (hazard ratio ¼ 0.45; 95% CI ¼ 0.27, 0.74, P ¼ 0.002). As we used acyclovir prophylaxis for patients who were CMV seropositive, we investigated whether this decrease in risk might be due to prophylactic antiviral use. We therefore limited the analysis to CMV-seronegative individuals and found that those with GVHD still experienced less of a risk of developing HZ than seronegative patients without GVHD (P-value ¼ 0.024). Thus, the results could not be attributed to prophylactic acyclovir administration. This effect of GVHD on hazard of infection was still present when the subgroup with positive VZV titers was analyzed. Importantly, those with prior GVHD who developed HZ had a greater risk of disseminated cutaneous involvement (P ¼ 0.016), although neither donor type (matched sibling vs unrelated donor), immune status prior to HSCT (see Definitions section above), nor TBI had any significant effect on the frequency of cutaneous or visceral dissemination. Only 7/63 (11%) patients received oral rather than i.v. therapy at diagnosis (see below); none of these patients developed disseminated cutaneous or visceral involvement.
Rising ALT is predictive of VZV infection
We collected data on AST, ALT, WBC, and PLT values in the 4 weeks preceding clinical presentation of HZ infection and for the period during infection. Two representative values preceding diagnosis and one representative value during infection were used to evaluate the presence of a significant trend over time. Of 37, 22 (59%) evaluable patients experienced a progressive increase in ALT level in the month preceding clinical diagnosis of HZ (Figure 2) . ALT values ranged from 32 to 2059 (median ¼ 52) and constituted a significant change in ALT using both twoand three-point models (P ¼ 0.02); while AST levels demonstrated a significant change only when a three-time point model was used (P ¼ 0.02) (data not shown). Transaminitis was not associated with concomitant GVHD (P ¼ 0.60) for patients having undergone allogeneic HSCT. No patients had documented infectious hepatitis although no routine screening algorithm was used for mild transaminasemia during the period of this study. No significant trends in WBC or PLT counts were observed (data not shown).
Treatment and factors affecting hospitalization
Information regarding initial treatment at diagnosis was available on 64 patients. Therapy at diagnosis of HZ was Table 3 Risk factors for HZ infection (entire cohort, n ¼ 310) Immune status group (prior chemotherapy for an underlying malignancy or primary immune deficiency) and conditioning with TBI were considered, but did not significantly add to the model. Immune status group (prior chemotherapy for an underlying malignancy or primary immune deficiency), conditioning with ATG, and unrelated or mismatched donor were considered, but did not significantly add to the model. Conditioning with TBI and tandem transplantation were considered, but did not significantly add to the model. unavailable on 13 patients who were initially evaluated elsewhere. Seven (11%) patients received oral acyclovir or famciclovir at diagnosis and two of these patients went on to require hospitalization for intravenous therapy. A total of 56 (89%) patients received a dose of intravenous therapy at diagnosis. In total, 48/64 patients (75%) who developed HZ were admitted to hospital for treatment of their infection. The length of hospital stay consisted of a median of 6 days (range 2-39 days). Length of stay was not significantly longer for patients who underwent allogeneic HSCT compared with those who underwent autologous HSCT (data not shown). For patients who underwent allogeneic HSCT, length of stay was significantly affected by cutaneous dissemination and visceral organ involvement (P ¼ 0.023 and P ¼ 0.034, respectively), but not by donor type (matched sibling vs unrelated donor), immune status prior to HSCT (see Definitions section above), prior acute or chronic GVHD, TBI or treatment with intravenous therapy at diagnosis. No risk factor had a significant effect on length of stay for patients who underwent autologous HSCT.
Risk factor
Discussion
HZ remains a significant problem in immunocompromised individuals, including those who have undergone HSCT. Here, we report the incidence of HZ in children undergoing either autologous or allogeneic HSCT at a single institution over a 7-year period. The incidence of HZ in our cohort of pediatric HSCT patients is consistent with the incidence rates previously reported. [4] [5] [6] [7] [8] [9] Additionally, our study demonstrates that although a substantial number of patients develop HZ in the early post-HSCT period, there is an increase in incidence over time and HZ can occur up to 5 years post-HSCT. This is particularly evident in the allogeneic cohort who, despite incidence rates of 34 and 50% at 12 months in all allogeneic patients and seropositive allogeneic patients, respectively, experiences a substantial increase over time such that 45 and 70% of these patients, respectively, have developed HZ by 60 months post-HSCT. This persistent propensity for opportunistic infection well after successful HSCT is in keeping with several studies that have documented a similar trend with other infections, including invasive aspergillus observed in patients surviving the immediate post-HSCT period. 20, 21 The significance of this delayed occurrence is particularly relevant to general pediatric oncologists and primary care providers, as HSCT patients will have likely returned to their care at the time of VZV reactivation. Our report, like most prior publications, [4] [5] [6] [7] [8] [9] includes all patients regardless of serologic status. Although our subset analysis in patients who had positive titers confirms that the seropositive patient is at particularly high risk for reactivation, it is important to note that not all patients who developed clinical evidence of HZ infection had documented positive VZV serology prior to HSCT and serologic status is often unknown when the patient is seen in follow-up, frequently at another institution.
Having established the incidence pattern of HZ infection post-HSCT in children, we wanted to evaluate which risk factors were most predictive of latent VZV reactivation. Our data demonstrate that patient age is the most important risk factor, with patients younger than 10 years of age having a significantly reduced risk of HZ infection across the entire cohort and all subgroups. One can postulate several reasons why younger children may be relatively protected, all of which are related to the rate of immune recovery following ablative therapy. Functioning T cells are essential in protecting against viral reactivation and younger children have been shown to have more rapid T-cell recovery following HSCT, 22, 23 likely reflecting relative thymic involution in older children and adults. The importance of thymic function in the generation of naı¨ve T cells as a major component of restoring the broad T-cell repertoire necessary to provide an effective immune response to viruses and other pathogens is well established. 23, 24 Although this information was not available for this retrospectively analyzed cohort, we speculate that younger children and/or their donors are more likely to have had recent exposure to wild-type or vaccine attenuated HZ prior to HSCT than older children. This may give them more extensive anti-VZV T cell memory, both by residual host and transferred donor immune cells, in the post-HSCT period. It is worth noting that a study of inactivated VZV vaccination in VZV seropositive adult autologous HSCT recipients vaccinated prior to and 30, 60, and 90 days after HSCT did not demonstrate a difference between the vaccinated group and controls until after repetitive post transplant revaccination. does not exclude an age-related effect of prior infection or vaccination on the rate of immune reconstitution by expanded memory T-cell populations in children. Our study points to a need to further investigate the parameters that influence varicella cell-mediated immunity across different age groups. A prospective trial could determine the relevance and predictive value of obtaining donor/ recipient VZV serology prior to HSCT. Other factors that increased the risk of VZV reactivation most likely did so by delaying the rate of immune reconstitution post-HSCT. Patients who underwent an allogeneic HSCT had a significantly higher risk of HZ infection than patients who received an autologous HSCT, presumably due to the greater pharmacologic and allogeneic-mediated immune suppression. 12, 26, 27 Among allogeneic HSCT recipients, conditioning with TBI approached significance as a risk factor when compared to conditioning with chemotherapy alone. 4, 28 However, patients who had underlying immunodeficiency or chemotherapy prior to HSCT did not demonstrate a greater risk of HZ infection compared with those presumed less compromised prior to HSCT. Acute or chronic GVHD had a protective effect on developing HZ. These surprising results were not attributable to the protective effects of concomitant CMV antiviral prophylaxis, since CMV-negative patients with GVHD who did not receive antiviral prophylaxis still experienced a reduced risk of developing HZ. Possibly, this observation is due to a masking of infectious symptoms and findings by either the immunosuppressive effects of GVHD or its treatment. However, we observed that those patients that developed clinical HZ following GVHD had a higher incidence of disseminated disease, suggesting that GVHD and/or its treatment negatively impact on the control of active clinical infection. Thus, some patients appear to be able to prevent VZV reactivation or maintain a subclinical presentation 29 even in the face of GVHD, while GVHD-related impairment of immunity causes a more fulminant course of HZ infection in other patients. The factors underlying these differences are poorly understood.
HZ infection post-HSCT in the pediatric population is associated with significant morbidity even in the postacyclovir era. Most of our patients were treated with oral or i.v. antiviral therapy, and, despite treatment, had an incidence of complications that parallels rates described in several adult studies. 1, 13, 26 Of 64 patients, 58 (91%) of the cohort with HZ reactivation were hospitalized to receive i.v. acyclovir. Length of stay was increased for patients with complications and management took place on the Stem Cell Transplant unit with the added psychological and economic implications of ICU-like care. The burden of illness for the pediatric patient population, including the high social and financial costs of inpatient therapy, are exacerbated by the relative lack of oral agents approved for young children and highlights the need for improved management strategies in this disease. Although some studies 6 have looked at VZV vaccination following HSCT to prevent reactivation, the timing and safety of immunization remain uncertain.
Our series of pediatric patients with HZ post-HSCT is the largest described in the literature to date and the first to document that a rising ALT level is significantly associated with the development of HZ infection. These changes in ALT levels appear to be predictive, as ALT elevation continued to be significant when analyzing only the two antecedent, rather than all three, time points. We hypothesize that the AST elevation, which was significant only when all three time points were included for analysis, more likely demonstrates a reactive phenomenon, with the peak change occurring during clinical infection. While we acknowledge that there are many causes of elevated ALT and AST post-HSCT, we believe that HZ should be included in the differential diagnosis of transaminitis in this patient population based on our data. Furthermore, in our cohort, the transaminitis appears to be specific, as the majority of patients with elevated levels did not have concomitant GVHD, which can independently cause liver dysfunction. We hypothesize that these patients go through a period of viremia prior to development of skin manifestations, which could provide a window in which to implement an early diagnostic test. Such patients may represent a good target group for screening with quantitative PCR similar to the current approach of screening for CMV reactivation. Thus, the inclusion of HZ infection post-HSCT in the differential diagnosis of patients with a rising ALT level, particularly if 410 years of age after allogeneic HSCT with TBI conditioning may allow for earlier initiation of therapy with less morbidity and decreased need for hospital admission.
